Medtronic Expands Board, Appoints Dr. Joon Lee

Medtronic ( (MDT) ) just unveiled an announcement.

On June 18, 2025, Medtronic‘s Board of Directors expanded from 10 to 11 members, appointing Dr. Joon Lee as a new independent director. Dr. Lee, CEO of Emory Healthcare, brings extensive experience in healthcare leadership and will serve on the Science and Technology Committee and the Compensation and Talent Committee. His appointment is expected to enhance Medtronic’s mission to leverage data and technology for improving patient and provider experiences, aligning with the company’s goals to advance healthcare solutions globally.

The most recent analyst rating on (MDT) stock is a Hold with a $87.00 price target. To see the full list of analyst forecasts on Medtronic stock, see the MDT Stock Forecast page.

Spark’s Take on MDT Stock

According to Spark, TipRanks’ AI Analyst, MDT is a Outperform.

Medtronic’s solid financial performance and strategic focus on high-margin growth areas drive its strong overall score. While technical indicators suggest a bearish trend, the stock’s fair valuation and attractive dividend yield provide a balanced outlook. The recent earnings call reinforces confidence in the company’s ability to navigate challenges such as tariffs and currency headwinds.

To see Spark’s full report on MDT stock, click here.

More about Medtronic

Medtronic plc, headquartered in Galway, Ireland, is a leading global healthcare technology company. It focuses on developing innovative solutions to address complex health challenges, offering products such as cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems. With a mission to alleviate pain, restore health, and extend life, Medtronic operates in over 150 countries with a workforce of more than 95,000 employees.

Average Trading Volume: 7,742,309

Technical Sentiment Signal: Buy

Current Market Cap: $110.7B

For a thorough assessment of MDT stock, go to TipRanks’ Stock Analysis page.